David A. Siegel Immuno Gen, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $9.61 Million - $23.1 Million	-771,400 Reduced 59.59%	523,118 $15.5 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $1.53 Million - $2.15 Million	108,400 Added 9.14%	1,294,518 $20.5 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $6.54 Million - $35 Million	-1,744,500 Reduced 59.53%	1,186,118 $22.4 Million
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $1.28 Million - $1.71 Million	-348,500 Reduced 10.63%	2,930,618 $11.3 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $1.21 Million - $1.68 Million	266,700 Added 8.85%	3,279,118 $16.3 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $831,488 - $1.2 Million	185,600 Added 6.57%	3,012,418 $14.4 Million
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $1.15 Million - $2.1 Million	364,900 Added 14.82%	2,826,818 $12.7 Million
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $1.28 Million - $2.26 Million	301,600 Added 13.96%	2,461,918 $11.7 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $59,831 - $94,470	12,596 Added 0.59%	2,160,318 $16 Million
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $4.15 Million - $5.45 Million	-826,596 Reduced 27.79%	2,147,722 $12.2 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $152,856 - $227,040	26,400 Added 0.9%	2,974,318 $19.6 Million
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $2.02 Million - $3.26 Million	310,000 Added 11.75%	2,947,918 $23.9 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $2.4 Million - $4.97 Million	649,100 Added 32.64%	2,637,918 $17 Million
Q3 2020 Nov 16, 2020	BUY	$3.45 - $4.89 $3.05 Million - $4.33 Million	885,200 Added 80.21%	1,988,818 $7.16 Million
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $330,672 - $531,864	99,600 Added 9.92%	1,103,618 $5.08 Million
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $745,604 - $2.39 Million	351,700 Added 53.92%	1,004,018 $3.42 Million
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $300,375 - $774,300	133,500 Added 25.73%	652,318 $3.33 Million
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $64,602 - $98,649	29,100 Added 5.94%	518,818 $1.26 Million
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $186,300 - $341,550	103,500 Added 26.8%	489,718 $1.06 Million
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $433,077 - $1.06 Million	179,700 Added 87.01%	386,218 $1.05 Million
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $446,732 - $1.1 Million	113,384 Added 121.74%	206,518 $991,000
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $1.93 Million - $2.53 Million	-224,500 Reduced 70.68%	93,134 $882,000
Q2 2018 Aug 14, 2018	SELL	$9.52 - $12.15 $3.49 Million - $4.46 Million	-366,818 Reduced 53.59%	317,634 $3.09 Million
Q1 2018 May 15, 2018	BUY	$6.7 - $12.95 $609,030 - $1.18 Million	90,900 Added 15.31%	684,452 $7.2 Million
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $3.01 Million - $4.7 Million	593,552	593,552 $3.81 Million

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account